Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23978956 | 1.00 | PNMT (0.54) | PNMTPGRSLC2A1SLC6A2SLC6A4 | |
| SCHEMBL26479456 | 0.88 | SLC2A1 (0.48) | PNMTPGRSLC2A1SLC6A2ADRB1 | |
| SCHEMBL19888756 | 0.87 | PNMT (0.46) | PNMTPGRSLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL16161632 | 0.85 | PNMT (0.53) | PNMTPGRSLC2A1SLC6A2SLC6A4 | |
| Ammonia Solution, Strong SCHEMBL5305718 | 0.85 | PNMT (0.51) | PNMTSLC2A1SLC6A2SLC6A4TAAR1 | |
| SCHEMBL19478606 | 0.83 | GBA1 (0.41) | PNMTPGRSLC2A1ADRB1ADRB3 | |
| SCHEMBL254476 | 0.82 | PGR (0.47) | PNMTPGRSLC2A1SLC6A2SLC6A4 | |
| SCHEMBL29428797 | 0.82 | PGR (0.47) | PNMTPGRSLC2A1SLC6A2SLC6A4 | |
| SCHEMBL18948879 | 0.81 | PNMT (0.45) | PNMTPGRSLC2A1AOC3ALDH1A1 | |
| SCHEMBL19492397 | 0.81 | PNMT (0.45) | PNMTPGRSLC2A1AOC3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | PNMT 2802/4885PGR 4008/4885SLC2A1 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.